Insights from 2023 ASH Annual Meeting
Playback speed
10 seconds
ASH 2023 Insights: "MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in R/R CLL From the CLL2-BAAG Trial"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Moritz Fürstenau
By
Insights from 2023 ASH Annual Meeting
FEATURING
Moritz Fürstenau
55 views
December 29, 2023
Login to view comments.
Click here to Login
Leukemia